ELV stock forecast, quote, news & analysis

Key Takeaways

• Elevance Health shares fell approximately 4% over the past 30 days, with the bulk of the decline occurring after its Q2 2026 earnings release on July 15.
• The company reported adjusted EPS of $7.45, beating consensus estimates of $6.21, and raised full-year 2026 adjusted EPS guidance to at least $27.00.
• Despite the headline beat, investors focused on deteriorating margins: adjusted operating margin fell to 3.6% from 5.0% a year earlier, while the Health Benefits segment operating margin dropped to 2.1%.
• Medical membership declined sequentially by 469,000 to approximately 44.9 million, driven by attrition in Medicaid, Medicare Advantage, and Individual ACA lines.
• Management characterized 2026 as a transition year and guided for at least 12% adjusted EPS growth in 2027, supported by accelerated investments in medical cost management and Carelon's integrated solutions.

Current Market Snapshot

Elevance Health (ELV) has experienced a turbulent stretch in recent weeks. After trading near the $427 level in mid-July ahead of its second-quarter earnings report, the stock sold off sharply even as the company posted stronger-than-expected results. The immediate catalyst was not the headline numbers — operating revenue of $49.8 billion and adjusted EPS of $7.45 both exceeded Wall Street forecasts — but rather the quality of those earnings and the direction of profitability metrics. Adjusted operating margin compressed 140 basis points year over year to 3.6%, while the benefit expense ratio rose 80 basis points to 89.7%, reflecting elevated medical cost trends in government-sponsored programs. The selloff rippled across the managed-care sector, dragging down peers such as UnitedHealth Group, Molina Healthcare, Humana, Centene, and CVS Health, as investors reassessed the near-term outlook for health insurers.

Elevance Health (ELV) Business Overview and Competitive Position

Elevance Health, headquartered in Indianapolis, Indiana, is one of the largest health benefits companies in the United States. Formerly known as Anthem, Inc., the company rebranded in 2022 to reflect its broader enterprise strategy. Elevance operates through four segments: Health Benefits, which includes its core insurance operations spanning Individual, Employer Group, Medicare, Medicaid, and BlueCard businesses; CarelonRx, its pharmacy benefit management unit; Carelon Services, which delivers behavioral health, palliative care, and other integrated health solutions; and Corporate & Other. With approximately 44.9 million medical members across its health plan portfolio, Elevance holds a dominant position in the employer-sponsored and government health insurance markets. The company's diversified model, strong balance sheet, and growing Carelon platform have historically made it a bellwether for the managed-care industry. Investors closely track Elevance for signals on medical cost trends, membership dynamics, and regulatory developments affecting the broader health insurance landscape.

Recent Developments Driving ELV

The most significant recent event was Elevance's Q2 2026 earnings report, released on July 15. The company exceeded consensus estimates on both the top and bottom lines, with adjusted EPS of $7.45 coming in approximately 20% above the $6.21 analyst consensus. Revenue of $49.8 billion also surpassed expectations. However, market reaction was decisively negative: the stock dropped more than 10% in a single session. Investors zeroed in on the fact that roughly $0.80 per share of the earnings beat stemmed from non-recurring below-the-line benefits rather than core operational strength. More concerning was the margin picture. The Health Benefits segment — Elevance's largest — saw its operating margin decline to 2.1% from 3.8% a year earlier, pressured by lower Medicaid reimbursement rates, elevated medical costs in government businesses, and the ongoing repositioning of its Medicare Advantage portfolio. CEO Gail K. Boudreaux emphasized that 2026 represents a transition year and announced accelerated investments in medical cost management, member experience, provider connectivity, and Carelon's value-based solutions. The company also raised its full-year adjusted EPS guidance to at least $27.00, up from the prior floor of $26.75, and lifted its operating cash flow forecast to at least $6.0 billion. On the capital allocation front, Elevance declared a quarterly dividend of $1.72 per share and continued its share repurchase program, buying back 0.7 million shares for $234 million during Q2. Additionally, the stock's sharp decline triggered broad-based selling across the managed-care sector, as investors interpreted Elevance's margin compression as potentially indicative of industry-wide headwinds.

Trending AI Robots

For traders seeking systematic, data-driven approaches to navigate volatile markets, Tickeron's Trending AI Robots page offers a curated view of top-performing algorithmic trading strategies. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across equities, ETFs, and forex markets. Only the highest-performing and most relevant bots appear in the Trending section, providing users with a streamlined way to identify strategies that have demonstrated recent success. These bots span a variety of trading styles — from short-term momentum plays to longer-duration swing strategies — and each bot's performance metrics, trading history, and strategy logic are transparently displayed. Exploring the Trending AI Robots page can help investors discover automated trading approaches aligned with their risk tolerance and market outlook.

2026 Outlook and What Investors Should Watch

Looking ahead, several key factors will shape ELV's trajectory through the remainder of 2026. First, Medicaid redetermination dynamics and state-level reimbursement rate adjustments will remain critical variables, as elevated medical cost trends in government programs continue to pressure margins. Second, the company's Medicare Advantage repositioning — including plan design changes and geographic exits — will be closely monitored for signs of stabilization. Third, the Carelon platform, encompassing pharmacy benefit management and integrated health services, represents a key growth engine; investors should watch for sustained revenue momentum and margin improvement in this segment. Fourth, Elevance's accelerated investment program in operating efficiency and provider connectivity will need to show measurable returns in the form of margin recovery. Fifth, the upcoming Q3 2026 earnings report will serve as an important checkpoint, with management indicating approximately 17% of full-year adjusted EPS expected in the third quarter. Finally, broader macroeconomic factors — including interest rate policy, labor market conditions affecting employer-sponsored enrollment, and potential regulatory changes in healthcare policy — will influence the sector's investment landscape. While Elevance's 12% adjusted EPS growth target for 2027 provides a constructive long-term framework, near-term execution on margin recovery and membership stabilization remains the focal point for Wall Street.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations